

SHORT COMMUNICATIONS

Thietanyl Protection in the Synthesis of 5-Aryloxy(sulfonyl)-3-bromo-1,2,4-triazoles

F. A. Khaliullin^a, E. E. Klen^{a,*} and N. N. Makarova^a

^a Bashkir State Medical University, ul. Lenina 3, Ufa, 450008 Bashkortostan, Russia

*e-mail: klen_elena@yahoo.com

Received May 8, 2018; revised October 10, 2018; accepted October 17, 2018

Abstract—Previously unknown 5-aryloxy- and 5-benzenesulfonyl-3-bromo-1*H*-1,2,4-triazoles have been synthesized starting from 3,5-dibromo-1,2,4-triazole by successive alkylation with 2-chloromethylthiirane, nucleophilic substitution of the 5-bromine atom by phenoxy or phenylsulfonyl group, oxidation of the thietane sulfur atom with hydrogen peroxide, and removal of the thietanyl protecting group by treatment with sodium ethoxide.

DOI: 10.1134/S1070428018120242

1,2,4-Triazole derivatives attract interest from both theoretical and practical viewpoints. In particular, these compounds are promising as pharmacologically active substances since they inhibit cytochrome P450-mediated processes [1] and synthesis of viral RNA and virus-specific proteins [2], selectively inhibit aromatase [3] and reuptake of serotonin at brain synapses, and act as 5-HT_{2A/2C} serotonin receptor antagonists [4]. 1,2,4-Triazole ring is a structural unit of many medicines used for the treatment of fungal and viral infections, malignant tumors, and psychic disorders [5]. Furthermore, 1,2,4-triazole derivatives are extensively studied as potential antidepressants, analgesics, and anti-inflammatory agents [6].


3,5-Disubstituted 1*H*-1,2,4-triazoles are convenient building blocks for the creation of combinatorial libraries of potential biologically active compounds; these syntheses utilize various protecting groups such as 3-oxobutyl [7], benzyl [8], diphenylmethyl [9],

2-methoxypropan-2-yl [10], tetrahydrofuran-2-yl [11], and cyanoethyl [12].

Herein, we propose to use a thietanyl protecting group [13] for the synthesis of previously unknown 5-aryloxy(sulfonyl)-3-bromo-1*H*-1,2,4-triazoles. This protecting group can be easily introduced by alkylation of 3,5-dibromo-1*H*-1,2,4-triazole with 2-chloromethylthiirane, it ensures subsequent reactions with nucleophiles, and is readily removed by treatment with sodium alkoxide after oxidation of the sulfur atom.


5-Substituted 3-bromo-1*H*-1,2,4-triazoles were synthesized in several steps. Initially, the reaction of 3,5-dibromo-1*H*-1,2,4-triazole with 2-chloromethylthiirane gave 3,5-dibromo-1-(thietan-3-yl)-1*H*-1,2,4-triazole (**1**) [14] which was treated with sodium phenoxides and sodium benzenethiolate to obtain 5-aryloxy(sulfonyl)-3-bromo-1-(thietan-3-yl)-1*H*-1,2,4-triazoles (Scheme 1) [15]. Compounds **2a–2g** were oxidized with hydrogen peroxides to the corre-

Scheme 1.



2, 3, R = PhO (**a**), 4-MeC₆H₄O (**b**), 3,4-Me₂C₆H₃O (**c**), 2-*i*-Pr-5-MeC₆H₃O (**d**), 2,4-Cl₂C₆H₃O (**e**), naphthalen-1-yloxy (**f**); **2g**, R = PhS; **3g**, R = PhSO₂.

Scheme 2.



R = PhO (**a**), 4-MeC₆H₄O (**b**), 3,4-Me₂C₆H₃O (**c**), 2-*i*-Pr-5-MeC₆H₃O (**d**), 2,4-Cl₂C₆H₃O (**e**), naphthalen-1-yloxy (**f**), R = PhSO₂ (**g**).

sponding thietane *S,S*-dioxides **3a–3g** [16]. The oxidation of the thietane sulfur atom in **2g** was accompanied by the transformation of the phenylsulfanyl group to benzenesulfonyl.

The thietanyl protection was readily removed by treatment of 5-substituted 3-bromo-1-(1,1-dioxo-λ⁶-thietan-3-yl)-1*H*-1,2,4-triazoles **3a–3g** with sodium ethoxide. We thus isolated 20–80% of 3-bromo-5-aryloxy(benzenesulfonyl)-1*H*-1,2,4-triazoles **4a–4g** and 3-ethoxythietane 1,1-dioxide (**5**) (Scheme 2).

The structure of the synthesized compounds was confirmed by elemental analyses and NMR and IR spectra, and their purity was checked by TLC. Unlike compounds **3a–3g**, the IR spectra of triazoles **4a–4g** contained an absorption band at 2642–3093 cm^{−1} due to stretching vibrations of associated N–H group, whereas no bands assignable to vibrations of sulfonyl group were present; these data confirmed elimination of the thietane dioxide ring with formation of 5-substituted 3-bromo-1*H*-1,2,4-triazoles. The ¹H NMR spectra of **4a–4g** lacked proton signals typical of thietane 1,1-dioxide fragment, while signals from protons of the substituent on C⁵ were present. For example, in the ¹H NMR spectrum of **4g** we observed three aromatic proton signals, a multiplet at δ 7.62–7.68 ppm, a triplet at δ 7.74 ppm, and a doublet at δ 7.95 ppm, which indicated conservation of the benzenesulfonyl group.

In keeping with the data of [17, 18], the ¹³C NMR spectra of **4a–4f** in CDCl₃ displayed only signals of the aromatic substituent, whereas signals of C³ and C⁵ of the triazole ring were not observed. Presumably, this is due to fast tautomeric transformations of compounds **4a–4f** in solution, which leads to considerable broadening of the ring carbon signals. The two-dimensional ¹H–¹⁵N HSQC and ¹H–¹⁵N HMBC spectra of **4b** showed no cross peaks between the NH proton (it resonated as a broadened singlet at δ 10.39 ppm in the ¹H NMR spectrum) and nitrogen atoms, which can also be explained by exchange processes. The ¹H–¹³C HMBC and ¹H–¹³C HSQC spectra of **4b** displayed

correlations of aromatic protons only with carbon atoms of the benzene ring and methyl group (Fig. 1).

Likewise, neither C³ nor C⁵ signal was detected in the ¹³C NMR spectra of **4c** in CD₃COOD and DMSO-*d*₆. Only the ¹³C NMR spectrum of **4g** in DMSO-*d*₆ showed signals at δ_C 134.08 and 161.67 ppm, which were assigned, respectively, to C³ and C⁵ of the triazole ring.

Thus, we have demonstrated the possibility of using thietanyl protection for the synthesis of difficultly accessible 5-aryloxy- and 5-benzenesulfonyl-3-bromo-1*H*-1,2,4-triazoles.

Compounds 4a–4g (general procedure). Metallic sodium, 0.27 g (11.6 mmol), was added to 25 mL of anhydrous ethanol, and the mixture was heated until hydrogen no longer evolved. 5-Substituted 3-bromo-1-(1,1-dioxo-λ⁶-thietan-3-yl)-1*H*-1,2,4-triazole **3a–3g**, 9.7 mmol, was then added, and the mixture was refluxed for 0.5 h. The solvent was distilled off under reduced pressure, the residue was treated with 5 mL of benzene and dissolved in 25 mL of water, and the mixture was acidified to pH 3 with dilute sulfuric acid. The precipitate was filtered off, washed with water, dried, and purified by reprecipitation with sulfuric acid from a solution in aqueous potassium hydroxide.

3-Bromo-5-phenoxy-1*H*-1,2,4-triazole (4a). Yield 0.84 g (36%), mp 95–97°C. IR spectrum, ν, cm^{−1}: 3065, 3036, 2945, 2842 (N–H), 1600, 1571, 1541, 1487 (C=N, C=C). ¹H NMR spectrum (CDCl₃), δ, ppm: 7.20–7.27 m (3H, H_{arom}), 7.36–7.41 m (2H,




Fig. 1. Correlations in the ¹H–¹³C HMBC spectrum of 3-bromo-5-(4-methylphenoxy)-1*H*-1,2,4-triazole (**4b**).

H_{arom}). ^{13}C NMR spectrum (CDCl_3), δ , ppm: 119.53 (C^2 , C^6), 125.91 (C^4), 129.94 (C^3 , C^5), 153.44 (C^1). Found, %: C 39.62; H 2.50; N 18.02. $\text{C}_8\text{H}_6\text{BrN}_3\text{O}$. Calculated, %: C 40.03; H 2.52; N 17.50.

3-Bromo-5-(4-methylphenoxy)-1H-1,2,4-triazole (4b). Yield 1.16 g (47%), mp 120–122°C. IR spectrum, ν , cm^{-1} : 3030, 2926, 2853, 2820, 2743, 2653 (N–H), 1561, 1501, 1489 (C=N, C=C). ^1H NMR spectrum (CDCl_3), δ , ppm: 2.32 s (3H, CH_3), 7.11 d (2H, 3'-H, 5'-H, $^3J = 8.5$ Hz), 7.16 d (2H, 2'-H, 6'-H, $^3J = 8.5$ Hz), 10.39 br.s (1H, NH). ^{13}C NMR spectrum (CDCl_3), δ_{C} , ppm: 20.86 (4'- CH_3), 119.46 (C^2 , C^6), 130.42 (C^3 , C^5), 135.80 (C^4), 151.22 (C^1). Found, %: C 42.87; H 3.10; N 16.83. $\text{C}_9\text{H}_8\text{BrN}_3\text{O}$. Calculated, %: C 42.54; H 3.17; N 16.54.

3-Bromo-5-(3,4-dimethylphenoxy)-1H-1,2,4-triazole (4c). Yield 1.85 g (71%), mp 133–134°C. IR spectrum, ν , cm^{-1} : 3023, 2939, 2918, 2848, 2734, 2642 (N–H), 1569, 1551, 1498, 1488 (C=N, C=C). ^1H NMR spectrum, δ , ppm: in CDCl_3 : 2.22 s (3H, 4'- CH_3), 2.24 s (3H, 3'- CH_3), 6.95 d.d (1H, 6'-H, $^3J = 8.2$, $^4J = 2.4$ Hz), 6.99 d (1H, 2'-H, $^4J = 2.2$ Hz), 7.11 d (1H, 5'-H, $^3J = 8.2$ Hz); in CD_3COOD : 2.24 s (3H, 4'- CH_3), 2.25 s (3H, 3'- CH_3), 6.98 d.d (1H, 6'-H, $^3J = 8.2$, $^4J = 2.4$ Hz), 7.05 d (1H, 2'-H, $^4J = 2.1$ Hz), 7.15 d (1H, 5'-H, $^3J = 8.3$ Hz); in $\text{DMSO}-d_6$: 2.17 s (3H, 4'- CH_3), 2.19 s (3H, 3'- CH_3), 6.94 d.d (1H, 6'-H, $^3J = 8.2$, $^4J = 2.1$ Hz), 7.02 d (1H, 2'-H, $^4J = 2.7$ Hz), 7.14 d (1H, 5'-H, $^3J = 8.2$ Hz). ^{13}C NMR spectrum, δ_{C} , ppm: in CDCl_3 : 19.18 (4'- CH_3), 19.98 (3'- CH_3), 116.81 (C^2), 120.68 (C^6), 130.73 (C^5), 134.52 (C^4), 138.50 (C^3), 151.30 (C^1); in CD_3COOD (125 MHz): 18.07 (4'- CH_3), 18.77 (3'- CH_3), 116.87 (C^2), 120.66 (C^6), 130.49 (C^5), 134.26 (C^4), 138.40 (C^3), 151.63 (C^1); in $\text{DMSO}-d_6$: 19.13 (4'- CH_3), 19.87 (3'- CH_3), 116.92 (C^2), 120.66 (C^6), 130.88 (C^5), 133.79 (C^4), 138.50 (C^3), 152.25 (C^1). Found, %: C 44.98; H 3.71; N 15.80. $\text{C}_{10}\text{H}_{10}\text{BrN}_3\text{O}$. Calculated, %: C 44.80; H 3.76; N 15.67.

3-Bromo-5-[5-methyl-2-(propan-2-yl)phenoxy]-1H-1,2,4-triazole (4d). Yield 0.57 g (20%), mp 139–140°C. IR spectrum, ν , cm^{-1} : 2961, 2926, 2866, 2736, 2651 (N–H), 1567, 1491 (C=N, C=C). ^1H NMR spectrum (CDCl_3), δ , ppm: 1.20 d [6H, $\text{CH}(\text{CH}_3)_2$, $^3J = 6.8$ Hz], 2.32 s (3H, 5'- CH_3), 3.10 d.d [1H, $\text{CH}(\text{CH}_3)_2$, $^3J = 6.8$ Hz], 6.99 d (1H, 6'-H, $^4J = 2.4$ Hz), 7.04 m (1H, 4'-H, $^3J = 8.4$, $^4J = 2.6$ Hz), 7.23 d (1H, 3'-H, $^3J = 8.5$ Hz). ^{13}C NMR spectrum (CDCl_3), δ_{C} , ppm: 19.43 (5'- CH_3), 23.22 [$\text{CH}(\text{CH}_3)_2$], 28.91 [$\text{CH}(\text{CH}_3)_2$], 117.14 (C^6), 121.02 (C^4), 126.21 (C^3), 137.21 (C^2), 144.78 (C^5), 150.80 (C^1). Found, %: C 49.01; H 4.57;

N 14.21. $\text{C}_{12}\text{H}_{14}\text{BrN}_3\text{O}$. Calculated, %: C 48.67; H 4.76; N 14.19.

3-Bromo-5-(2,4-dichlorophenoxy)-1H-1,2,4-triazole (4e). Yield 1.17 g (39%), mp 126–128°C. IR spectrum, ν , cm^{-1} : 3093, 3068, 3021, 2962, 2853, 2737 (N–H), 1591, 1568, 1475 (C=N, C=C). ^1H NMR spectrum (CDCl_3), δ , ppm: 7.29 d (1H, 5'-H, $J = 2.3$ Hz), 7.31 s (1H, 3'-H), 7.45 d (1H, 6'-H, $J = 2.2$ Hz). ^{13}C NMR spectrum (CDCl_3), δ_{C} , ppm: 123.00 (C^6), 126.96 (C^4), 128.34 (C^5), 130.65 (C^3), 132.12 (C^2), 147.88 (C^1). Found, %: C 30.94; H 1.30; N 13.48. $\text{C}_8\text{H}_4\text{BrCl}_2\text{N}_3\text{O}$. Calculated, %: C 31.10; H 1.31; N 13.60.

3-Bromo-5-(naphthalen-1-yloxy)-1H-1,2,4-triazole (4f). Yield 2.25 g (80%), mp 112–113°C. IR spectrum, ν , cm^{-1} : 3024, 2949, 2845, 2740, 2650 (N–H), 1582, 1557, 1489 (C=N, C=C). ^1H NMR spectrum (CDCl_3), δ , ppm: 7.32–7.52 m (4H, 2'-H, 3'-H, 6'-H, 7'-H), 7.70 d (1H, 4'-H, $^3J = 8.1$ Hz), 7.83 d (1H, 8'-H, $^3J = 8.0$ Hz), 8.00 d (1H, 5'-H, $^3J = 8.1$ Hz). ^{13}C NMR spectrum (CDCl_3), δ_{C} , ppm: 115.41 (C^8), 120.99 (C^4), 125.42 (C^7), 125.89 (C^9), 126.05 (C^3), 126.73 (C^5), 126.85 (C^2), 127.95 (C^6), 134.82 (C^{10}), 149.23 (C^1). Found, %: C 49.79; H 2.86; N 14.40. $\text{C}_{12}\text{H}_8\text{BrN}_3\text{O}$. Calculated, %: C 49.68; H 2.78; N 14.48.

3-Bromo-5-benzenesulfonyl-1H-1,2,4-triazole (4g). Yield 0.83 g (30%), mp 203–205°C. IR spectrum, ν , cm^{-1} : 3064, 2951, 2873, 2735, 2667 (N–H), 1421, 1373 (C=N, C=C), 1340, 1161 (SO_2). ^1H NMR spectrum ($\text{DMSO}-d_6$), δ , ppm: 7.62–7.68 m (2H, 3'-H, 5'-H), 7.74 t (1H, 4'-H, $^3J = 7.4$ Hz), 7.95 d (2H, 2'-H, 6'-H, $^3J = 7.2$ Hz). ^{13}C NMR spectrum ($\text{DMSO}-d_6$), δ_{C} , ppm: 127.80 (C^2 , C^6), 129.62 (C^3 , C^5), 134.08 (C^3), 134.20 (C^4), 139.61 (C^1), 161.67 (C^5). Found, %: C 33.31; H 2.43; N 14.77. $\text{C}_8\text{H}_6\text{BrN}_3\text{O}_2\text{S}$. Calculated, %: C 33.35; H 2.10; N 14.58.

The IR spectra were recorded in KBr on an Infra-lyum FT-02 spectrometer. The ^1H and ^{13}C NMR spectra were measured on a Bruker AV-500 instrument at 500 and 125 MHz, respectively, relative to the residual proton and carbon signals of the deuterated solvent. The elemental analyses were obtained on a Hekatech Euro 3000 CHNS analyzer. The melting points were determined with a Stuart SMP30 melting point apparatus.

REFERENCES

1. Espinel-Ingroff, A., *Encyclopedia of Microbiology*, Schaechter, M., Ed., Amsterdam: Elsevier, 2009, 3rd ed., p. 205.

2. Loustaud-Ratti, V., Debette-Gratien, M., Jacques, J., Alain, S., Marquet, P., Sautereau, D., Rousseau, A., and Carrier, P., *World J. Hepatol.*, 2016, vol. 8, p. 123.
3. Geisler, J., *Br. J. Cancer*, 2011, vol. 104, p. 1059.
4. Fagiolini, A., Comandini, A., Dell'Osso, M.C., and Kasper, S., *CNS Drugs*, 2012, vol. 26, p. 1033.
5. Al-Masoudi, I.A., Al-Soud, Y.A., Al-Salihi, N.J., and Al-Masoudi, N.A., *Chem. Heterocycl. Compd.*, 2006, vol. 42, p. 1377.
6. Zhou, C.-H. and Wang, Y., *Curr. Med. Chem.*, 2012, vol. 19, p. 239.
7. Kofman, T.P., *Russ. J. Org. Chem.*, 2001, vol. 37, p. 1158.
8. Zumburn, A., *Synthesis*, 1998, p. 1357.
9. Tolstyakov, V.V. and Tselinskii, I.V., *Russ. J. Gen. Chem.*, 2004, vol. 74, p. 399.
10. Shimizu, S., Endo, T., Izumi, K., and Mikamiyama, H., *Org. Process Res. Dev.*, 2007, vol. 11, p. 1055.
11. Bradshaw, J.S., Nielsen, R.B., Tse, P.-K., Arena, G., Wilson, B.E., Dalley, N.K., Lamb, J.D., Christensen, J.J., and Izatt, R.M., *J. Heterocycl. Chem.*, 1986, vol. 23, p. 361.
12. Tolstyakov, V.V., *Chem. Heterocycl. Compd.*, 2017, vol. 53, p. 719.
13. Khaliullin, F.A. and Klen, E.E., *Russ. J. Org. Chem.*, 2009, vol. 45, p. 135.
14. Klen, E.E., Khaliullin, F.A., and Iskhakova, G.F., *Russ. J. Org. Chem.*, 2005, vol. 41, p. 1847.
15. Klen, E.E., Makarova, N.N., Khaliullin, F.A., Alekhin, E.K., Nikitina, I.L., Ivanova, O.A., and Gabidullin, R.A., *Bashk. Khim. Zh.*, 2008, vol. 15, p. 112.
16. Klen, E.E., Nikitina, I.L., Makarova, N.N., Miftakhova, A.F., Ivanova, O.A., Khaliullin, F.A., and Alekhin, E.K., *Pharm. Chem. J.*, 2016, vol. 50, p. 642.
17. Buzykin, B.I., Mironova, E.V., Nabiullin, V.N., Azanchev, N.M., Avvakumova, L.V., Rizvanov, I.Kh., Gubaidullin, A.T., Litvinov, I.A., and Syakaev, V.V., *Russ. J. Gen. Chem.*, 2008, vol. 78, p. 461.
18. Khomenko, D.M., Doroshchuk, R.O., Vashchenko, O.V., and Lampeka, R.D., *Chem. Heterocycl. Compd.*, 2016, vol. 52, p. 402.